Patent intelligence · US
US 11225506
Cell penetrating peptides and methods of making and using thereof
Cell penetrating peptides and methods of making and using thereof
Patent details — US 11225506
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 18, 2022
- Expiration
- Jan 13, 2042
- Applicant
- Entrada Therapeutics, Inc.
- Claims
- 41
- CPC classes
- A61K, A61K38/05, A61K38/12, A61K38/465
Quick answer
US 11225506 (Cell penetrating peptides and methods of making and using thereof) is held by Entrada Therapeutics, Inc.. Status: granted. Granted Jan 18, 2022. Expires Jan 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Entrada Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 41
- CPC classes
- A61K, A61K38/05, A61K38/12, A61K38/465, A61K47/64, A61K49/0039
More from Entrada Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11987821
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 11168310
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 10815276
Cell penetrating peptides and methods of making and using thereof
granted -
US 10626147
Cell penetrating peptides and methods of making and using thereof
granted
Frequently asked questions
What is US patent 11225506?
US 11225506 (Cell penetrating peptides and methods of making and using thereof) is held by Entrada Therapeutics, Inc.. Status: granted. Granted Jan 18, 2022. Expires Jan 13, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11225506?
Entrada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11225506 expire?
Our index shows an expiration date of Jan 13, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.